the Company’s lead autoimmune program with potential to transform treatment across a broad spectrum of autoimmune and inflammatory diseases Advanced research and development of CUE-501 as lead ...

Ronnie O’Sullivan is on the hunt for the perfect cue ahead of the World Snooker Championship. The 49-year-old is yet to find ...

Short interest in Cue Biopharma Inc (NASDAQ:CUE) decreased during the last reporting period, falling from 1.10M to 1.02M. This put 1.62% of the company's publicly available shares short.

Research and development expenses were $36.3 million and $40.8 million for the years ended December 31, 2024 and 2023, ...